Bendamustine in the treatment of patients with indolent non‐Hodgkin lymphoma refractory or relapse to rituximab treatment: An open‐label, single‐agent, multicenter study in China

Author:

Gao Yan1,Liu Yizhen2ORCID,Wang Yafei3,Zhang Qingyuan4,Wu Depei5,Ye Xu6,Wu Jianqiu7,Xu Wei8,Zhou Jianfeng9,Yang Yu10,Cen Hong11,Zhang Feng12,Xiang Ying13,Tang Xiaoqiong14,Ding Kaiyang15,Lin JinYing16,Ma Lei17,Wang Shunqing18,Yu Hao19,Zhao Yang20,Song Bin21ORCID,Lv Fangfang2,Huang Huiqiang1

Affiliation:

1. Sun Yat‐Sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou China

2. Department of Medical Oncology Fudan University Shanghai Cancer Center Department of Oncology Shanghai Medical College Fudan University Shanghai China

3. Department of Hematology Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer Key Laboratory of Cancer Prevention and Therapy Tianjin China

4. Department of Medical Oncology Harbin Medical University Cancer Hospital Harbin China

5. Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China

6. Department of Hematology The Second Affiliated Hospital of Guangzhou Medical University Guangzhou China

7. Department of Medical Oncology Jiangsu Institute of Cancer Research Jiangsu Red Cross Cancer Center Jiangsu Cancer Hospital the Affiliated Hospital of Nanjing Medical University Nanjing China

8. Hematology Department Jiangsu Province Hospital Nanjing China

9. Hematology Department Tongji Medical College Huazhong University of Science and Technology Wuhan China

10. Department of Lymphoma and Head and Neck Cancer The Affiliated Tumor Hospital of Fujian Medical University Fuzhou Fujian Province China

11. Department of Hematology Lymphoma and Pediatric Oncology Guangxi Medical University Affiliated Tumor Hospital and Oncology Medical College Nanning China

12. Department of Hematology Anhui Oncology Hospital Bengbu Medical College Bengbu China

13. Department of Hematology and Oncology Chongqing Cancer Hospital Chongqing China

14. The First Affiliated Hospital of Chongqing Medical University Chongqing China

15. Department of Hematology Provincial Hospital Affiliated to Anhui Medical University Hefei Anhui Province China

16. Department of Hematology People's Hospital of Guangxi Zhuang Autonomous Region Nanning China

17. Guangzhou Medical University Affiliated Tumor Hospital and Oncology Medical College Nanning China

18. Department of Hematology Guangzhou First People's Hospital Guangzhou Guangdong China

19. Department of Biostatistics Nanjing Medical University Nanjing China

20. Nanjing Baosida Pharmaceutical Technology Co., Ltd Nanjing China

21. West China Hospital of Sichuan University Sichuan China

Publisher

Wiley

Subject

Cancer Research,Oncology

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3